News
-
17Aug. 2022Hadasit portfolio company Enlivex Therapeutics has received approval for initiation the multicenter Phase I/II Trial of Allocetra
Enlivex Therapeutics (Nasdaq: ENLV), Hadasit portfolio company, has received Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a…
-
8Mar. 2022Promising results of the novel cell therapy against progressive Multiple Sclerosis in its latest clinical trial
NeuroGenesis and Hadassah Medical Center Report Positive NF-L Biomarker Results from a Phase 2 Study in Progressive Multiple Sclerosis Treated with NG-01 Cells Therapy. This technology developed by NeuroGenesis biotech…
-
1Mar. 2022Hadassah Digital Health Accelerator Cohort 4 Graduation
Hadassah Accelerator powered by IBM Alpha Zone held a very successful Demo day on February 28th presenting 5 promising medical startups graduating from the Cohort #4: Little One Care Futura…
-
21Dec. 2021רוש רוכשת מליניאג’ את זכויות הפיתוח והשיווק של סלקיור
חברת ליניאג’ האמריקאית הנסחרת בבורסה בתל אביב הודיעה כי חתמה על עסקה עם חברת ג’ננטק מקבוצת תאגיד הבריאות רוש, לפיו רוש תפתח, תייצר ותשווק את המוצרים של חברת ‘סלקיור מקבוצת…
-
20Dec. 2021Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), today announced that Lineage and its subsidiary, Cell Cure Neurosciences Ltd., have entered into an exclusive worldwide collaboration and license agreement…
-
11Oct. 2021Three Israeli hospitals make Newsweek’s list of top cardiology centers
World’s Best Specialized Hospitals – Cardiology 2021 – Newsweek” includes Hadassah Hospital Heart Institute at Ein Kerem in Jerusalem in a ranking of top-tier global medical centers.
-
16Jun. 2021KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
Proceeds will enable further clinical development of DSP107, a first-in-class CD47x41BB targeting fusion protein, for the treatment of solid and hematological tumors and accelerate the path towards clinical development of…
-
2Jun. 2021
-
8Apr. 2021Hadassah and MyBiotics to Collaborate for the Discovery of Microbiome-Based Therapy for Improving Cancer Immunotherapy
We are pleased to announce Hadassah important collaboration with MyBiotics for the Discovery of Microbiome-Based Therapy for Improving Cancer Immunotherapy
-
10Feb. 2021פיתוח חדש יאפשר לראשונה מעקב בזמן אמת במהלך ניתוחי מוח מורכבים
הטכנולוגיה נולדה בתוכנית ביודיזיין של האוניברסיטה העברית בשיתוף המרכז הרפואי הדסה